References
- M. F. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons, A. L. Catapano, M. Cooney, U. Corrà, B. Cosyns, C. Deaton, I. Graham, M. S. Hall, F. D. R. Hobbs, M. Løchen, H. Löllgen, P. Marques-Vidal, J. Perk, E. Prescott, J. Redon, D. J. Richter, N. Sattar, Y. Smulders, M. Tiberi, H. B. van der Worp, I. van Dis, W. M. M. Verschuren and S. Binno, 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur. Heart J. 37 (2016) 2315–2381; https://doi.org/10.1093/eurheartj/ehw10610.1093/eurheartj/ehw106
- J. L. Fleg, G. W. Stone, Z. A. Fayad, J. F. Granada, T. S. Hatsukami, F. D. Kolodgie, J. Ohayon, R. Pettigrew, M. S. Sabatine, G. J. Tearney, S. Waxman, M. J. Domanski, P. R. Srinivas and J. Narula, Detection of high-risk atherosclerotic plaque: report of the NHLBI working group on current status and future directions, JACC Cardiovasc. Imag. 5 (2012) 941–955; https://doi.org/10.1016/j.jcmg.2012.07.00710.1016/j.jcmg.2012.07.007
- P. Libby, P. M. Ridker and G. K. Hansson, Inflammation in atherosclerosis: From pathophysiology to practice, J. Am. Coll. Cardiol. 54 (2009) 2129–2138; https://doi.org/10.1016/j.jacc.2009.09.00910.1016/j.jacc.2009.09.009
- L. H. Kuller, R. P. Tracy, J. Shaten and E. N. Meilahn, Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial, Am. J. Epidemiol. 144 (1996) 537–547; https://doi.org/10.1093/oxfordjournals.aje.a00896310.1093/oxfordjournals.aje.a008963
- P. M. Ridker, N. Rifai, L. Rose, J. E. Buring and N. R. Cook, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N. Engl. J. Med. 347 (2002) 1557–1565; https://doi.org/10.1056/NEJMoa02199310.1056/NEJMoa021993
- S. Kaptoge, E. Di Angelantonio, G. Lowe, M. B. Pepys, S. G. Thompson, R. Collins and J. Danesht, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis, Lancet 375 (2010) 132–140; https://doi.org/10.1016/S0140-6736(09)61717-710.1016/S0140-6736(09)61717-7
- V. Lubrano and S. Balzan, Consolidated and emerging inflammatory markers in coronary artery disease, World J. Exp. Med. 5 (2015) 21–32; https://doi.org/10.5493/wjem.v5.i1.2110.5493/wjem.v5.i1.21
- I. Subirana, M. Fitó, O. Diaz, J. Vila, A. Francés, E. Delpon, J. Sanchis, R. Elosua, D. Muñoz-Aguayo, I. R. Dégano and J. Marrugat, Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism, Sci. Rep. 8 (2018) Article ID 3191; https://doi.org/10.1038/s41598-018-21482-y10.1038/s41598-018-21482-y
- E. Diamantis, G. Kyriakos, L. V. Quiles-Sanchez, P. Farmaki and T. Troupis, The anti-inflammatory effects of statins on coronary artery disease: An updated review of the literature, Curr. Cardiol. Rev. 13 (2017) 209–216; https://doi.org/10.2174/1573403X1366617042610461110.2174/1573403X13666170426104611
- F. Mach, C. Baigent, A. L. Catapano, K. C. Koskinas, M. Casula, L. Badimon, M. J. Chapman, G. G. De Backer, V. Delgado, B. A. Ference, I. M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T. R. Pedersen, G. Riccardi, D. J. Richter, M. S. Sabatine, M. Taskinen, L. Tokgozoglu and O. Wiklund, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), Eur. Heart J. 41 (2020) 111–188; https://doi.org/10.1093/eurheartj/ehz45510.1093/eurheartj/ehz455
- D. Tousoulis, C. Psarros, M. Demosthenous, R. Patel, C. Antoniades and C. Stefanadis, Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins, J. Am. Coll. Cardiol. 63 (2014) 2491–2502; https://doi.org/10.1016/j.jacc.2014.01.05410.1016/j.jacc.2014.01.054
- C. Demir, C. Anil, Y. Bozkus, U. Mousa, A. Kut, A. Nar and N. B. Tutuncu, Do statins affect thyroid volume and nodule size in patients with hyperlipidemia in a region with mild-to-moderate iodine deficiency? A Prospective Study, Med. Princ. Pract. 27 (2018) 1–7; https://doi.org/10.1159/00048674810.1159/000486748
- M. L. Muiesan, C. Agabiti-Rosei, A. Paini and M. Salvetti, Uric acid and cardiovascular disease: An update, Eur. Cardiol. 11 (2016) 54–59; https://doi.org/10.15420/ecr.2016:4:210.15420/ecr.2016:4:2
- G. Derosa, P. Maffioli, Ž. Reiner, L. E. Simental-Mendía and A. Sahebkar, Impact of statin therapy on plasma uric acid concentrations: A systematic review and meta-analysis, Drugs 76 (2016) 947–956; https://doi.org/10.1007/s40265-016-0591-210.1007/s40265-016-0591-2
- D. Ferro, S. Parrotto, S. Basili, C. Alessandri and F. Violi, Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia, J. Am. Coll. Cardiol. 36 (2000) 427–431; https://doi.org/10.1016/S0735-1097(00)00771-310.1016/S0735-1097(00)00771-3
- E. Mandosi, M. Fallarino, A. Gatti, A. Carnovale, M. Rossetti, E. Lococo, B. Buchetti, S. Filetti, L. Lenti and S. Morano, Atorvastatin downregulates monocyte CD36 expression, nuclear NFkB and TNF-a levels in type 2 diabetes, J. Atheroscler. Thromb. 17 (2010) 539–545; https://doi.org/10.5551/jat.295610.5551/jat.2956
- T. Lyngdoh, P. Vollenweider, G. Waeber and P. M. Vidal, Association of statins with inflammatory cytokines: a population based Colaus study, Atherosclerosis 219 (2011) 253–258; https://doi.org/10.1016/j.atherosclerosis.2011.07.11710.1016/j.atherosclerosis.2011.07.117
- P. Karmaus, M. Shi, S. Perl, A. Biancotto, J. Candia, F. Cheung, Y. Kotliarov, N. Young and M. B. Fessler, Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol, JCI Insight 4 (2019) e131530; https://doi.org/10.1172/jci.insight.13153010.1172/jci.insight.131530
- I. Karu, J. Starkopf, K. Zilmer and M. Zilmer, Growth factors serum levels in coronary artery disease patients scheduled for bypass surgery: Perioperative dynamics and comparisons with healthy volunteers, BioMed Res. Int. 2013 (2013) Article ID 985404; https://doi.org/10.1155/2013/98540410.1155/2013/985404
- C. Camaré, M. Pucelle, A. Nègre-Salvayre and R. Salvayre, Angiogenesis in the atherosclerotic plaque, Redox Biol. 12 (2017) 18–34; https://doi.org/10.1016/j.redox.2017.01.00710.1016/j.redox.2017.01.007
- J. Dulak and A. Józkowicz, Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti--cancer therapy, Curr. Cancer Drug Targets 5 (2005) 579–594; https://doi.org/10.2174/15680090577493282410.2174/156800905774932824
- M. Weis, C. Heeschen, A. J. Glassford and J. P. Cooke, Statins have biphasic effects on angiogenesis, Circulation 105 (2002) 739–745; https://doi.org/10.1161/hc0602.10339310.1161/hc0602.103393
- A. Giurgea, C. Margeta, T. Maca, A. Rezaie-Majd, R. A. Bucek, M. Manavi, R. Afarideh, E. Minar and M. Baghestanian, Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients, J. Cardiovasc. Pharmacol. 47 (2006) 30–36; https://doi.org/10.1097/01.fjc.0000191970.65998.7a10.1097/01.fjc.0000191970.65998.7a
- H. F. Alber, J. Dulak, M. Frick, W. Dicht, S. P. Schwarzacher, O. Pachinger and F. Weidinger, Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease, J. Am. Coll. Cardiol. 39 (2002) 1951–1955; https://doi.org/10.1016/S0735-1097(02)01884-310.1016/S0735-1097(02)01884-3
- V. Capra and G. E. Rovati, Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents, Pulm. Pharmacol. Ther. 27 (2014) 10–16; https://doi.org/10.1016/j.pupt.2013.06.00510.1016/j.pupt.2013.06.005
- K. Yokohama, S. Fukunishi, M. Ii, K. Nakamura, H. Ohama, Y. Tsuchimoto A. Asai, Y. Tsuda and K. Higuchi, Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice, Int. J. Mol. Med. 38 (2016) 1499–1506; https://doi.org/10.3892/ijmm.2016.276610.3892/ijmm.2016.2766
- S. Cantoni, C. Cavallini, F. Bianchi, F. Bonavita, V. Vaccari, E. Olivi, I. Frascari, R. Tassinari, S. Valente, V. Lionetti and C. Ventura, Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway, Pharmacol. Res. 65 (2012) 275–284; https://doi.org/10.1016/j.phrs.2011.12.00410.1016/j.phrs.2011.12.004
- V. G. Chantzichristos, A. P. Agouridis, E. Moutzouri, K. Stellos, M. S. Elisaf and A. D. Tselepis, Plasma VEGF and IL-8 levels in patients with mixed dyslipidaemia. Effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 fatty acids: A pilot study, Curr. Vasc. Pharmacol. 14 (2016) 474–480; https://doi.org/10.2174/157016111466616040412534110.2174/1570161114666160404125341